Aridis Pharmaceuticals Inc. Common Stock
ARDS
ARDS was delisted on the 18th of July, 2023.
6 hedge funds and large institutions have $411K invested in Aridis Pharmaceuticals Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 2 closing their positions.
14% less funds holding
Funds holding: 7 → 6 (-1)
45% less capital invested
Capital invested by funds: $747K → $411K (-$336K)
50% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 2
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$23.7K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$26 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$74.5K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$40.4K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$6K |
| 4 |
Morgan Stanley
New York
|
-$2K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$1.53K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $331K | -$40.4K | -7,664 | -9% |
|
|
2
Millennium Management
New York
| $51K | -$74.5K | -14,123 | -55% |
|
|
3
BlackRock
New York
| $25K | +$23.7K | +4,493 | +368% |
|
|
4
UBS Group
Zurich,
Switzerland
| $3K | -$1.53K | -291 | -28% |
|
5
Wells Fargo
San Francisco,
California
| $1K | – | – | – |
|
|
6
Victory Capital Management
San Antonio,
Texas
| – | -$6K | -934 | Closed |
|
|
7
Morgan Stanley
New York
| – | -$2K | -229 | Closed |
|
|
8
Bank of America
Charlotte,
North Carolina
| – | +$26 | +5 | New |
|
ARDS Hedge Fund Activity: Q4 2019 in Review
6 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in Aridis Pharmaceuticals Inc. Common Stock (ARDS) for Q4 2019, worth a combined $411K — down 45% from $747K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of ARDS and 1 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 1 added.
The largest buyer was BlackRock, adding an estimated $23.7K. The largest seller was Millennium Management, cutting an estimated $74.5K.
- 6 institutional investors held Aridis Pharmaceuticals Inc. Common Stock (ARDS) as of Q4 2019, down from 7 in Q3 2019.
- Funds reported $411K of Aridis Pharmaceuticals Inc. Common Stock stock for Q4 2019, down 45% quarter-over-quarter.
- 1 fund opened new Aridis Pharmaceuticals Inc. Common Stock positions in Q4 2019 and 2 closed out, a net change of -1 holder.
- The largest Aridis Pharmaceuticals Inc. Common Stock buyer in Q4 2019 was BlackRock, an estimated $23.7K added.
- The largest Aridis Pharmaceuticals Inc. Common Stock seller in Q4 2019 was Millennium Management, an estimated $74.5K sold.
Based on aggregated 13F filings for Q4 2019.